Odyssey Therapeutics presented a $433 million cash balance as of June 30, with expected funding for operations into H2 2028. For investors, the stated runway frames the company’s development plans, including an October 2026 update for OD-001 and a H2 2026 CTA filing for OD-002.
Key Highlights
- The company reports $433 million in cash as of June 30, 2026, with expected operations funding into H2 2028.
- OD-001 is expected to generate updated monotherapy data in October 2026 at UEG.
- OD-002 has a CTA filing anticipated in H2 2026, followed by Phase 1/2 initiation in H1 2027.
Odyssey Therapeutics, Inc. (NASDAQ: ODTX) outlined a $433 million cash balance as of June 30 and said it expects the funds to support operations into H2 2028. The presentation also set out clinical milestones for its inflammatory and autoimmune disease programs.
$433 Million Cash Balance and Clinical Milestones
The September 2026 presentation identifies OD-001 as a small-molecule program for ulcerative colitis and Crohn’s disease. Updated monotherapy data are expected in October 2026 at UEG, followed by a H2 2027 Phase 2a combination readout and a H2 2027 Phase 2b monotherapy readout. OD-002, another small-molecule program, targets cutaneous lupus erythematosus, nephropathies and B cell-mediated diseases, with a CTA filing planned for H2 2026 and Phase 1/2 initiation in H1 2027. Odyssey also lists OD-003, a protein program for atopic dermatitis, systemic lupus erythematosus and alopecia areata, and OD-004, a protein program for chronic obstructive pulmonary disease and asthma. The company says its Balance Sheet is expected to fund operations into H2 2028.
Inflammatory Bowel Disease Market Information
Odyssey identifies inflammatory bowel disease as a $100B current market. It also lists a $30B current market and $65B future market, and a $25B current market and $40B future market, for other disease areas.
FAQs
Q: What cash balance did Odyssey Therapeutics report?
A: Odyssey Therapeutics reported $433 million in cash as of June 30. The company expects that balance to fund operations into H2 2028.
Q: What are Odyssey Therapeutics’ next clinical milestones?
A: OD-001 is expected to provide updated monotherapy data in October 2026 at UEG. OD-002 has a CTA filing planned for H2 2026.
Q: What did Odyssey report for ulcerative colitis remission?
A: The presentation reported a 27% clinical remission rate in moderate-to-severe ulcerative colitis patients. It said similar activity was observed among advanced-therapy-experienced patients.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.